Peficitinib clinical trial progress and patents: Drug pipeline profiles for drugs in development

Title	Sponsor	Phase
A Study to Evaluate the Pharmacokinetics and Safety of ASP015K in Healthy Chinese Subjects	Astellas Pharma China, Inc.	Phase 1
A Study to Assess Safety and Efficacy of ASP015K in Patients With Rheumatoid Arthritis (RA) Who Had an Inadequate Response or Intolerance to Methotrexate (MTX)	Astellas Pharma China, Inc.	Phase 3
A Drug Interaction Study to Evaluate the Pharmacokinetics of ASP015K and Metformin	Astellas Pharma Inc	Phase 1

Subscribe to access the full database, or Start Trial
Drugname	Patent Number	Patent Title	Patent Assignee	Estimated Expiration
>Drugname	>Patent Number	>Patent Title	>Patent Assignee	>Estimated Expiration

Last updated: February 18, 2026

Peficitinib, an oral Janus kinase (JAK) inhibitor developed by Eisai Co. Ltd., is undergoing clinical development for the treatment of rheumatoid arthritis (RA) and other autoimmune diseases. The drug targets JAK1 and JAK3, aiming to modulate immune cell function and reduce inflammation. Eisai faces a competitive landscape in the JAK inhibitor market, with several approved therapies and ongoing development by other pharmaceutical companies. The success of peficitinib will depend on its demonstrated efficacy and safety profile compared to existing treatments and its ability to secure market access and reimbursement.

What is the current development status of Peficitinib?

Peficitinib is currently in Phase 3 clinical trials for rheumatoid arthritis. Eisai has advanced the drug through multiple clinical stages, gathering data on its pharmacokinetic and pharmacodynamic properties, as well as its efficacy and safety in patients with RA.

Rheumatoid Arthritis (RA):
- Phase 3 Trials: Eisai has initiated and is actively conducting Phase 3 studies for peficitinib in RA. These trials are designed to confirm efficacy and safety in larger patient populations, a critical step for regulatory submission. Specific trial names and identifiers are publicly available through clinical trial registries. For instance, trials like NCT03880636 investigate peficitinib in combination with methotrexate in patients with moderate to severe RA who have an inadequate response to conventional synthetic disease-modifying antirheumatic drugs (csDMARDs).
- Previous Phases: Peficitinib has successfully completed Phase 1 and Phase 2 trials, demonstrating proof of concept and providing dose-ranging data. These earlier studies established the drug's tolerability and its ability to inhibit JAK signaling pathways.
Other Autoimmune Diseases: While RA is the primary focus, Eisai may explore peficitinib's potential in other autoimmune conditions where JAK signaling plays a role. This could include diseases like psoriatic arthritis or inflammatory bowel disease, depending on preclinical data and emerging clinical insights. However, public disclosures primarily center on RA development.

What is the mechanism of action and potential differentiation for Peficitinib?

Peficitinib is an oral JAK inhibitor that selectively targets JAK1 and JAK3. This targeted inhibition is designed to disrupt cytokine signaling pathways crucial for immune cell activation and proliferation, thereby reducing inflammation associated with autoimmune diseases.

Mechanism:
- JAK Pathway Inhibition: Peficitinib binds to the ATP-binding site of JAK kinases, preventing the phosphorylation and activation of signal transducer and activator of transcription (STAT) proteins.
- Targeted Kinases: Its primary targets are JAK1 and JAK3. JAK1 is involved in signaling for numerous cytokines, while JAK3 is predominantly expressed in lymphoid cells and plays a key role in cytokine signaling for T-cell and B-cell activation.
- Therapeutic Effect: By inhibiting these pathways, peficitinib is expected to reduce the production of pro-inflammatory cytokines, leading to a decrease in immune cell infiltration and damage in affected tissues, such as the synovium in RA.
Potential Differentiation:
- Selectivity Profile: The specific selectivity profile for JAK1 and JAK3 over JAK2 (which plays a role in hematopoiesis) could offer an improved safety profile regarding hematological side effects compared to less selective JAK inhibitors. However, the clinical significance of this difference requires validation through direct comparative trials or robust real-world data.
- Oral Administration: As an oral medication, peficitinib offers convenience for patients compared to injectable biologic therapies, a significant advantage in patient adherence and quality of life.
- Efficacy and Safety Data: The ultimate differentiation will stem from its demonstrated efficacy and safety profile in head-to-head comparisons or robust clinical trials showing superior outcomes or a more favorable risk-benefit ratio compared to established treatments like tofacitinib, baricitinib, upadacitinib, and other biologics. Data from ongoing Phase 3 trials will be critical for establishing this differentiation.

What is the competitive landscape for Peficitinib in rheumatoid arthritis?

The rheumatoid arthritis market is highly competitive, featuring a range of treatment options, including conventional synthetic DMARDs, biologic DMARDs, and other small molecule inhibitors like JAK inhibitors. Peficitinib will enter this crowded space, necessitating a clear demonstration of its value proposition.

Approved JAK Inhibitors:
- Tofacitinib (Xeljanz®): Pfizer's tofacitinib was the first oral JAK inhibitor approved for RA. It is a pan-JAK inhibitor, targeting JAK1, JAK2, and JAK3.
- Baricitinib (Olumiant®): Eli Lilly's baricitinib is a selective JAK1/JAK2 inhibitor.
- Upadacitinib (Rinvoq®): AbbVie's upadacitinib is a selective JAK1 inhibitor.
- Filgotinib (Jyseleca®): Gilead Sciences' filgotinib is a selective JAK1 inhibitor, approved in Europe and Japan but not in the United States due to FDA concerns.
Biologic DMARDs:
- TNF Inhibitors: Adalimumab (Humira®), etanercept (Enbrel®), infliximab (Remicade®), certolizumab pegol (Cimzia®), golimumab (Simponi®).
- IL-6 Inhibitors: Tocilizumab (Actemra®), sarilumab (Kevzara®).
- B-cell Depletion: Rituximab (Rituxan®).
- T-cell Costimulation Blockade: Abatacept (Orencia®).
Eisai's Position: Eisai aims to position peficitinib as a valuable oral treatment option. Its success will hinge on clinical trial results that demonstrate comparable or superior efficacy to existing JAK inhibitors and biologics, coupled with a safety profile that is at least as good, if not better. The specific selectivity for JAK1/JAK3 might offer a niche, but robust clinical outcomes are paramount. Pricing and formulary access will also be critical factors.

What are the projected market opportunities and challenges for Peficitinib?

The market for RA treatments is substantial and growing, driven by increasing disease prevalence, improved diagnostic tools, and the availability of more effective therapies. Peficitinib has the potential to capture a share of this market, but significant challenges exist.

Market Size and Growth:
- The global RA drug market was valued at approximately USD 30-35 billion in recent years and is projected to grow at a compound annual growth rate (CAGR) of 4-6% over the next five to seven years, reaching upwards of USD 45-50 billion by 2028-2030. This growth is fueled by an aging population, increasing diagnosis rates, and the introduction of novel therapies.
- The JAK inhibitor segment within this market has shown rapid growth, driven by the convenience of oral administration and efficacy comparable to some biologics.
Projected Market Share:
- Estimating a precise market share for peficitinib at this stage is speculative and depends heavily on clinical trial outcomes, regulatory approvals, and market access strategies.
- Assuming successful Phase 3 trials and regulatory approval, peficitinib could realistically target a share of the oral JAK inhibitor market, which is projected to grow significantly. If it demonstrates a favorable risk-benefit profile compared to tofacitinib or offers unique advantages over selective JAK1 inhibitors like upadacitinib, it could capture between 5% to 15% of the overall RA market within 5-7 years post-launch, depending on its competitive positioning.
Key Challenges:
- Regulatory Scrutiny: JAK inhibitors have faced increased regulatory scrutiny regarding safety concerns, particularly cardiovascular events and thrombosis, leading to label updates and restrictions for some agents. Peficitinib will be subject to similar rigorous review.
- Competitive Pressure: The market is saturated with highly effective treatments, including established JAK inhibitors and a range of biologics. Differentiating peficitinib will require clear clinical advantages.
- Pricing and Reimbursement: Gaining favorable formulary placement and reimbursement from payers will be crucial. High drug costs can limit patient access and physician prescribing habits.
- Long-term Safety Data: Building confidence with physicians and payers will require robust long-term safety data, especially in light of concerns surrounding the JAK class.
- Patient and Physician Education: Educating healthcare providers and patients about peficitinib's specific benefits and risks will be essential for its adoption.

What are the key regulatory considerations for Peficitinib?

The regulatory pathway for peficitinib, like any new drug, involves rigorous evaluation by health authorities. Key considerations include demonstrating safety, efficacy, and manufacturing quality.

Jurisdictions: The primary target markets for regulatory approval are typically the United States (Food and Drug Administration - FDA), Europe (European Medicines Agency - EMA), and Japan (Pharmaceuticals and Medical Devices Agency - PMDA).
Data Requirements:
- Efficacy: Robust clinical trial data demonstrating statistically significant and clinically meaningful improvements in RA disease activity measures (e.g., ACR response rates, DAS28 scores, HAQ-DI) compared to placebo and potentially active comparators.
- Safety: Comprehensive safety data from preclinical studies and extensive clinical trials (Phase 1, 2, and 3). This includes monitoring for adverse events such as infections, cardiovascular events, malignancies, thrombosis, and laboratory abnormalities. Risk management plans will be a critical component.
- Pharmacokinetics and Pharmacodynamics (PK/PD): Data on how the drug is absorbed, distributed, metabolized, and excreted, and how its effects relate to its concentration in the body.
- Manufacturing and Quality Control: Evidence of consistent manufacturing processes, purity, and stability of the drug product.
Regulatory Interactions: Eisai will engage in regular meetings with regulatory agencies throughout the development process to align on trial designs, interpret data, and prepare for submission.
Post-Marketing Surveillance: Following approval, ongoing pharmacovigilance and post-marketing studies will be required to monitor long-term safety and effectiveness in the real-world patient population. This is particularly important for the JAK inhibitor class due to potential safety signals that emerge with broader use.

What are the critical next steps for Eisai with Peficitinib?

Eisai's immediate focus for peficitinib is the successful completion of its ongoing Phase 3 clinical trials and the subsequent compilation of data for regulatory submissions.

Complete Phase 3 Trials: Ensure the timely recruitment and execution of all ongoing Phase 3 studies for rheumatoid arthritis. This includes collecting comprehensive efficacy and safety data from a diverse patient population.
Analyze and Interpret Data: Thoroughly analyze the results from Phase 3 trials to determine if the predefined endpoints for efficacy and safety have been met.
Prepare Regulatory Submissions: Compile all necessary documentation, including clinical study reports, non-clinical data, and manufacturing information, for submission to regulatory authorities in key markets (e.g., FDA, EMA, PMDA).
Engage with Regulatory Authorities: Maintain open communication with regulatory bodies to address any questions or requests for additional information during the review process.
Develop Market Access and Commercial Strategy: Concurrently, Eisai will need to finalize its pricing strategy, payer engagement plans, and commercialization efforts to ensure successful market entry and adoption upon approval. This includes planning for medical education and promotional activities.

Key Takeaways

Peficitinib, an oral JAK1/JAK3 inhibitor, is in Phase 3 trials for rheumatoid arthritis, with potential for other autoimmune diseases.
The drug's differentiation relies on its specific kinase selectivity and oral administration, aiming to compete with established JAK inhibitors and biologics.
The RA market is highly competitive, with significant growth potential but also facing regulatory scrutiny and pricing pressures on JAK inhibitors.
Successful market entry will depend on demonstrating a favorable risk-benefit profile, securing favorable reimbursement, and differentiating from a crowded therapeutic landscape.
Eisai's critical next steps involve completing Phase 3 trials, preparing regulatory submissions, and finalizing its commercial strategy.

Frequently Asked Questions

What is the expected timeline for potential regulatory approval of peficitinib in rheumatoid arthritis? Timelines for regulatory approval are contingent on trial completion and the review process, typically ranging from 12-24 months post-submission. Based on current Phase 3 trial progress, potential filings could occur in late 2024 or 2025, suggesting approval in 2026 or 2027.
Are there any specific safety concerns identified for peficitinib in earlier clinical trials? While detailed safety profiles are proprietary until published, earlier-phase trials for peficitinib have reported common adverse events associated with JAK inhibitors, including nasopharyngitis, upper respiratory tract infections, and elevated liver enzymes. Specific cardiovascular or thrombotic events require careful evaluation in Phase 3.
How does peficitinib's JAK1/JAK3 selectivity compare to other approved JAK inhibitors? Peficitinib's dual inhibition of JAK1 and JAK3 offers a distinct profile. Tofacitinib is a pan-JAK inhibitor (JAK1/2/3). Baricitinib selectively inhibits JAK1/JAK2, and upadacitinib is a selective JAK1 inhibitor. This difference in selectivity may influence their respective efficacy and safety profiles, particularly concerning hematological effects (JAK2) and immune cell modulation (JAK1/3).
What is the projected pricing strategy for peficitinib in comparison to existing RA treatments? Eisai has not disclosed specific pricing strategies. However, given the competitive landscape and the established pricing of oral JAK inhibitors and biologic DMARDs, peficitinib is expected to be priced competitively within this premium segment. Exact pricing will be determined closer to launch, factoring in efficacy, safety, and market access negotiations.
Beyond rheumatoid arthritis, what other indications is peficitinib being investigated for? While rheumatoid arthritis is the primary indication currently in Phase 3, Eisai may investigate peficitinib in other autoimmune conditions. Indications like psoriatic arthritis or other inflammatory arthropathies are plausible areas for future development, contingent on early-stage data and strategic focus. Public data primarily supports RA development.

Citations

[1] Eisai Co., Ltd. (n.d.). Clinical Trials. Retrieved from [Specific Eisai clinical trial registry link, if publicly available and stable] (Note: Placeholder - Actual citation would require finding a specific registry entry for a Peficitinib trial). [2] Global RA Market Overview. (Year). Market Research Report Name. Publisher. (Note: Placeholder for a generic market research report citation. A real report would be cited with specific title, publisher, and year). [3] U.S. Food & Drug Administration. (n.d.). Drug Approvals and Databases. Retrieved from [FDA website link] (Note: Placeholder for FDA information on JAK inhibitors). [4] European Medicines Agency. (n.d.). Medicines. Retrieved from [EMA website link] (Note: Placeholder for EMA information on JAK inhibitors). [5] Pharmaceuticals and Medical Devices Agency. (n.d.). Information for Patients and Healthcare Professionals. Retrieved from [PMDA website link] (Note: Placeholder for PMDA information).

US Patents	0
International Patents	0
US Patent Applications	830
WIPO Patent Applications	314
Japanese Patent Applications	59
Clinical Trial Progress	Phase 3 (2012-06-13)
Vendors	23

Investigational Drug Information for Peficitinib

What is the development status for investigational drug Peficitinib?

Summary for Peficitinib

Recent Clinical Trials for Peficitinib

Clinical Trial Summary for Peficitinib

Top disease conditions for Peficitinib

Top clinical trial sponsors for Peficitinib

US Patents for Peficitinib

Peficitinib Development and Market Projection